AI in Clinical Trial Feasibility: Separating Hype from High-Impact Tools in 2026

Verdict: most AI sold for clinical trial feasibility in 2026 is repackaged site-history reporting. The tools that genuinely reduce enrolment risk do three narrow things well — they quantify the eligible population against your protocol, they model site activation rather than site prestige, and they force a documented go/no-go decision with a date on it. Everything else is a dashboard.

IQVIA's May 2026 blog on the growing role of real-world evidence in clinical trials is a reasonable marker of where the field has landed: real-world evidence has moved from a regulatory curiosity into the trial-design conversation, which is exactly why the bar for "AI-powered feasibility" has to rise with it.

Key takeaways

• The differentiator is provenance, not model architecture. A feasibility number you cannot trace to a source is a guess with a decimal point.
• EHR-derived population counts fail on phenotype definition far more often than on data volume.
• Site selection models that rank sites on historical enrolment alone tend to reproduce the same over-used sites and the same underperformance.
• Protocol optimisation is where AI pays back fastest, because amendments are the most expensive thing you can avoid.
• Ask every vendor what their model got wrong last year. The answer tells you more than the accuracy claim.

What defines 'high-impact' AI in clinical trial feasibility today?

High-impact AI in clinical trial feasibility produces a decision-grade number — an eligible patient estimate, an activation timeline, a probability of hitting enrolment — that is traceable to a named source, scoped to your protocol, and dated. Anything that produces a score without a denominator is a marketing artefact. The distinction is not sophistication; it is auditability.

The last row matters most. Every feasibility model I have seen fail in practice failed quietly — a site that never activated, a screen-failure rate nobody modelled. A vendor who cannot describe their error modes has not looked for them.

How is AI used for patient population analysis with EHR and real-world data?

AI is used to turn EHR and real-world data into protocol-specific eligible-population estimates, but accuracy is governed by phenotype definition, not data volume. Two vendors querying the same claims database with different inclusion logic can differ by an order of magnitude on the same indication. The model is rarely the bottleneck; the case definition is.

The practical sequence that holds up:

1. Write the eligibility criteria as executable logic — every lab threshold, prior therapy, and washout window as a rule.
2. Run that logic against the RWD source and count patients who survive all criteria, not each criterion separately.
3. Apply a screen-failure haircut derived from comparable completed trials, not a generic 20%.
4. Re-run the count with a widened or narrowed criterion to see how elastic the population is.

That fourth step is where AI earns its keep, because it answers the question sponsors actually care about: which single criterion is costing me the most patients? IQVIA's 2026 piece on real-world evidence in clinical trials and Diligent Pharma's overview of real-world data and evidence companies are both useful orientation on what these sources can and cannot support.

AI in site selection clinical trials: beyond historical performance

AI site selection should predict which sites will activate on time and enrol to target for this protocol, not which sites enrolled well in a different one. Historical performance is a weak prior: it is confounded by indication mix, prior sponsor relationship, and how much hand-holding the last CRO provided. Predictive models that lean on it mostly rediscover the same academic centres everyone else is queuing for.

What actually moves the needle:

• Feasibility questionnaire response quality — how fast and how specifically a site answers, treated as a signal rather than paperwork.
• Prior trial experience in the exact indication, weighted by recency.
• Local eligible-population density from RWD, not from the site's own estimate.
• Competing trials open in the same catchment, which is the single most under-modelled variable in my experience.
• Activation risk — IRB turnaround, contract cycle, staffing churn.

A model that outputs "Tier 1 / Tier 2 / Tier 3" is not predictive. A model that outputs "this site has a 40% chance of being active in 90 days and a 25% chance of hitting 12 patients in 12 months, and here is the competing-trial load behind that" is.

AI protocol optimization: can it reduce amendments and patient burden?

AI protocol optimisation can meaningfully reduce amendments, because most amendments trace to a small number of design choices — visit schedules, eligibility strictness, and endpoint definitions — that can be stress-tested before first-patient-in. The gains come from simulating burden and feasibility, not from generating prose. Lifebit's AI clinical trial optimisation guide covers the design-side use cases in more depth than most vendor pages.

Three checks worth running on any protocol before it locks:

• Visit burden simulation. Count procedures per visit against the population you actually expect to enrol — often elderly, often working, often travelling.
• Eligibility elasticity. Which criterion, if relaxed by one increment, adds the most eligible patients for the least scientific loss?
• Endpoint measurability. Can the sites you have actually measure this endpoint to the required standard, on the schedule you have specified?

A protocol that is scientifically elegant and operationally impossible is not a protocol. It is a delay with a document number.

How does predictive analytics in clinical trials change enrolment risk and go/no-go decisions?

Predictive analytics changes go/no-go decisions by converting enrolment from a hope into a probability distribution you can argue about. Instead of "we think 40 sites will do it," you get a modelled distribution of enrolment completion dates with the assumptions exposed. That is the difference between a decision and a bet.

In practice, a defensible go/no-go needs four modelled inputs: eligible population per site, expected activation curve, screen-failure rate, and competing-trial attrition. If any of those four is a point estimate with no range, the verdict is not yet decision-grade.

The discipline I would insist on: write the kill criterion before you see the model output. If the model then says the trial needs 18 months longer than your funding runway supports, you have an answer rather than a debate. Most teams run the model first and negotiate the threshold afterwards, which is how trials that should have been stopped get started.

AI patient recruitment in clinical trials 2026: what actually works?

In 2026 the AI recruitment tools that work are the unglamorous ones: pre-screening against structured eligibility logic, triage of inbound interest, and site-level outreach prioritisation. Broad "AI finds patients" platforms still struggle with the same problem they had three years ago — the eligible patient exists, but they are not in the channel you are advertising in. Rework.ai's roundup of AI tools for clinical trial patient recruitment in 2026 is a fair survey of the current vendor set.

What to hold vendors to:

• Does the tool screen against the full protocol, or only a headline condition?
• What is the false-positive rate at the site, measured after site review?
• Does it integrate with the site's workflow, or does it generate a list someone must re-enter?
• What happens to a patient who screens out — are they routed anywhere useful?

Recruitment AI that increases site workload is worse than no recruitment AI.

AI clinical trial matching: the piece most teams get wrong

AI clinical trial matching works reasonably well as a pre-screening filter and badly as a substitute for site judgement. The failure mode is consistent: the model optimises for matching a patient to a trial, while the site optimises for a patient who will complete it. Adherence, distance, caregiver support, and competing comorbidities decide completion, and those are the variables least present in structured data.

Treat matching output as a queue for a human, with an explicit false-positive budget. If the site has to review 200 matches to find 10 screenable patients, you have automated the wrong half of the problem.

Case studies: what real-world AI impact looks like in 2025-2026

Publicly available case studies from this period are almost all vendor-authored and unaudited, so treat them as hypotheses rather than evidence. The honest position: there is no neutral, third-party registry of AI feasibility outcomes I would stake a go/no-go on. What you can do instead is run your own backtest.

Take two or three of your own completed trials. Feed the protocol and the site list to the tool. Ask it to predict enrolment before you show it the actual result. Then compare. That single exercise tells you more about a vendor than any reference call, and it costs you a fortnight rather than a trial.

Evaluating AI tools: key questions for biotech founders and clinical teams

Evaluate AI feasibility tools on provenance, backtest performance, and error transparency — in that order. Model sophistication is the least informative thing about a vendor. The checklist below is the one I would actually run.

1. Source traceability. Can I click through from every number to its origin?
2. Protocol specificity. Does it ingest my actual eligibility criteria, or a disease category?
3. Backtest evidence. Will you run it against my completed trials, blind?
4. Error modes. Where did the model perform worst last year, and why?
5. Update cadence. How often does the underlying data refresh, and how do I know?
6. Output format. Do I get a verdict with assumptions, or a dashboard to interpret?
7. Total cost. Licence plus the analyst time to operate it, honestly estimated.

If a vendor will not do number three, stop there.

What's next for AI in drug development beyond 2026?

Beyond 2026, the pressure moves from model quality to evidence quality — regulators and investors will want the same traceability from AI-assisted feasibility that they expect from any other trial input. Expect the interesting work to sit in two places: linking feasibility models to actual enrolment outcomes so they self-correct, and standardising how real-world data sources are described so two teams querying the same source get comparable answers.

The teams that win this are not the ones with the cleverest model. They are the ones who kept a record of what they predicted and what happened, and used it.

---

If you want to see what a fully cited feasibility assessment looks like rather than a score, Clinical Trial OS runs a six-pillar assessment and returns a go/no-go verdict in hours, with every number linked to its public source. Worth a look before your next site list is locked.

FAQ

What is AI clinical trial feasibility?

AI clinical trial feasibility is the use of models over real-world data, EHRs, and historical trial data to estimate whether a protocol can enrol and complete at a given set of sites. Done properly it produces traceable estimates of eligible population, activation timing, and enrolment probability — not a single confidence score.

Can AI actually predict clinical trial enrolment accurately?

Not to a point estimate, and anyone promising that is overselling. Useful models produce a range with assumptions exposed — eligible population, activation curve, screen-failure rate, competing-trial attrition. Accuracy improves sharply when the model is backtested against your own completed trials rather than a vendor's reference set.

How do I choose an AI site selection tool?

Insist on a blind backtest against two or three of your completed trials, ask which variables drive the ranking, and check whether competing trials in the same catchment are modelled. If the tool ranks sites mainly on historical enrolment volume, it will push you toward the same over-subscribed centres as everyone else.

Is AI patient recruitment worth the cost in 2026?

It is worth it when it reduces site workload — pre-screening, triage, and outreach prioritisation. It is not worth it when it generates a list of leads that sites must manually re-qualify. Ask for the post-review false-positive rate before you sign anything.

What should a go/no-go feasibility verdict actually contain?

Four modelled inputs with ranges: eligible population per site, expected activation timeline, screen-failure rate, and competing-trial attrition. Plus a kill criterion written before the model output is reviewed. A verdict without those is a recommendation, not a decision.